FGF21 and metabolic dysfunction-associated steatohepatitis: FGF21, a recently recognized metabolic regulator of glucose and lipid metabolism as well as energy homeostasis [49], has gained significant attention as a promising therapeutic agent for metabolic disorders, including NASH, T2DM, and obesity [50–53].